Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

被引：8
|
作者：
Bosanquet, N [1 ]
Yeates, A
机构：
[1] Imperial Coll Sch Med, London, England
[2] Eisai Europe Ltd, London, England
来源：
PHARMACOECONOMICS | 2006年 / 24卷 / 06期
关键词：
D O I：
10.2165/00019053-200624060-00008
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：623 / 625
页数：3
相关论文
共 50 条
  • [1] Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease
    Colin Green
    Joanna Picot
    Emma Loveman
    Andrea Takeda
    Jo Kirby
    Andrew Clegg
    PharmacoEconomics, 2005, 23 : 1271 - 1282
  • [2] Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease
    Green, C
    Picot, J
    Loveman, E
    Takeda, A
    Kirby, J
    Clegg, A
    PHARMACOECONOMICS, 2005, 23 (12) : 1271 - 1282
  • [3] Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease
    Nick Bosanquet
    Andrew Yeates
    PharmacoEconomics, 2006, 24 : 623 - 625
  • [4] Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease - The authors' reply
    Green, C
    Picot, J
    Loveman, E
    Takeda, A
    Kirby, J
    Clegg, A
    PHARMACOECONOMICS, 2006, 24 (06) : 625 - 626
  • [5] Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea
    Suh, Guk-Hee
    VALUE IN HEALTH, 2009, 12 : S49 - S54
  • [6] Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain
    Antonanzas, F
    Badenas, J
    François, C
    Guilhaume, C
    VALUE IN HEALTH, 2003, 6 (06) : 765 - 765
  • [7] Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease -: A Markov model in Finland
    François, C
    Sintonen, H
    Sulkava, R
    Rive, B
    CLINICAL DRUG INVESTIGATION, 2004, 24 (07) : 373 - 384
  • [8] Cholinesterase inhibitors in Alzheimer's disease - Are they worth the cost?
    Whitehouse, PJ
    CNS DRUGS, 1999, 11 (03) : 167 - 173
  • [9] Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease - A review with methodological considerations
    Wimo, A
    DRUGS & AGING, 2004, 21 (05) : 279 - 295
  • [10] Treatment of Alzheimer's disease with cholinesterase inhibitors in Germany: A cost-effectiveness study
    Faltraco, F
    Happich, M
    Reisig, V
    Teipel, SJ
    Moeller, HJ
    Hampel, H
    NEUROBIOLOGY OF AGING, 2004, 25 : S336 - S336
12345